Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1951 4
1952 1
1960 1
1962 1
1963 3
1964 1
1965 1
1968 1
1969 1
1970 1
1971 1
1974 2
1975 2
1980 1
1981 1
1982 2
1983 1
1984 4
1987 8
1988 3
1989 4
1990 6
1991 2
1992 3
1993 8
1994 9
1995 10
1996 9
1997 9
1998 10
1999 10
2000 12
2001 12
2002 6
2003 1
2004 5
2005 5
2006 13
2007 7
2008 7
2009 11
2010 5
2011 12
2012 16
2013 15
2014 13
2015 26
2016 18
2017 13
2018 18
2019 13
2020 19
2021 8
2022 21
2023 12
2024 17
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Baselga J, et al. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149875 Free PMC article. Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Discovery and development of an oral analgesic targeting the α2B adrenoceptor.
Toyomoto M, Kurihara T, Nakagawa T, Inoue A, Kimura R, Kii I, Sawada T, Ogihara T, Nagayasu K, Kishi T, Onogi H, Im D, Asada H, Iwata S, Taguchi J, Sumida Y, Yoshida S, Aoki J, Hosoya T, Hagiwara M. Toyomoto M, et al. Among authors: taguchi j. Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2500006122. doi: 10.1073/pnas.2500006122. Epub 2025 Aug 7. Proc Natl Acad Sci U S A. 2025. PMID: 40773228
Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Nakazawa Y, Miyano M, Tsukamoto S, Kogai H, Yamamoto A, Iso K, Inoue S, Yamane Y, Yabe Y, Umihara H, Taguchi J, Akagi T, Yamaguchi A, Koga M, Toshimitsu K, Hirayama T, Mukai Y, Machinaga A. Nakazawa Y, et al. Among authors: taguchi j. Nat Commun. 2024 Mar 11;15(1):2192. doi: 10.1038/s41467-024-46167-1. Nat Commun. 2024. PMID: 38467634 Free PMC article.
Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer.
Koido S, Taguchi J, Shimabuku M, Kan S, Bito T, Misawa T, Ito Z, Uchiyama K, Saruta M, Tsukinaga S, Suka M, Yanagisawa H, Sato N, Ohkusa T, Shimodaira S, Sugiyama H. Koido S, et al. Among authors: taguchi j. J Immunother Cancer. 2024 Oct 8;12(10):e009765. doi: 10.1136/jitc-2024-009765. J Immunother Cancer. 2024. PMID: 39384197 Free PMC article. Clinical Trial.
MYCL-mediated reprogramming expands pancreatic insulin-producing cells.
Hirano M, So Y, Tsunekawa S, Kabata M, Ohta S, Sagara H, Sankoda N, Taguchi J, Yamada Y, Ukai T, Kato M, Nakamura J, Ozawa M, Yamamoto T, Yamada Y. Hirano M, et al. Among authors: taguchi j. Nat Metab. 2022 Feb;4(2):254-268. doi: 10.1038/s42255-022-00530-y. Epub 2022 Feb 10. Nat Metab. 2022. PMID: 35145326
Synthesis of Acylboron Compounds.
Wu D, Taguchi J, Tanriver M, Bode JW. Wu D, et al. Among authors: taguchi j. Angew Chem Int Ed Engl. 2020 Sep 21;59(39):16847-16858. doi: 10.1002/anie.202005050. Epub 2020 Jul 20. Angew Chem Int Ed Engl. 2020. PMID: 32510826 Review.
407 results